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Chapter 8
Summary and general discussion
122 Chapter 8
The main focus of this thesis was to establish the best pharmacological treatment 
for unipolar psychotic depression.
 Review and meta-analysis
The Cochrane review described in chapter 2 included all randomised controlled 
trials performed up to April 2004. Of 3333 potentially relevant articles screened, 
only 10 were included in the review. This low number indicates that this severe 
form of depression is seriously underinvestigated. On the basis of the limited 
evidence available at that moment, we concluded that antidepressant monotherapy, 
with addition of an antipsychotic if the patient does not respond, or treatment 
with a combination of an antidepressant plus an antipsychotic both appear to be 
appropriate options for patients with unipolar psychotic depression. However, in 
clinical practice the balance between the risks and benefits of these treatments 
favours the first option for many patients. Antipsychotic monotherapy as initial 
treatment is not appropriate.
 Guidelines
Because many guidelines recommend, often emphatically, treatment with 
a combination of an antidepressant plus an antipsychotic as first choice, we 
investigated the evidence used to support this recommendation (chapter 3). To this 
end, we screened all major guidelines for the pharmacological treatment of psychotic 
depression, using the AGREE instrument (Appraisal of Guidelines for Research & 
Evaluation1) to evaluate the quality of the guidelines. In addition, we evaluated the 
quality of all the references mentioned in these guidelines. We concluded that the 
NICE guideline scored the highest for quality, followed by the Dutch, Australian, 
and American guidelines. It became clear that the conclusions and advice given 
in guidelines are not always consistent with the evidence on which they are based. 
Thus on the basis of current guidelines, it is not clear how patients with psychotic 
depression can best be treated pharmacologically. 
 Randomised clinical trial (RCT)
Because the design used for our randomised double-blind multicentre trial might 
be useful for future studies, we described the double-blinding of medication and 
the double-blind, dose-titration of imipramine in detail in chapter 4. The study 
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design proved successful in that we did not lose patients for logistic reasons and 
adequate blood levels were achieved in all imipramine-treated patients. The results 
of the trial are decribed in chapter 5.
 Trial design
The study proved logistically feasible but difficult to perform. Before the start of 
the trial, we carried out a 3-month pilot study involving all the participating centres 
in which we screened all patients for inclusion criteria and assessed whether 
patients could be motivated to participate in the trial. On base of this pilot study, we 
estimated that we would be able to recruit 180 patients in 3 years (60 patients/year). 
In practice, however, we recruited 120 patients in 5 years (24 patients/year). This 
is consistent with the feared Law of Lasagna,2 by which suitable patients disappear 
at the start of the study only to re-appear again once the study has stopped. On the 
basis of this experience, we advise not only performing a pilot study but also at least 
halving the number of patients that you think you can recruit to a RCT. 
Four of the 11 centers that agreed to participate were ultimately not able to 
recruit patients. Despite intensive efforts to change the situation, the organisation 
of patient care and research in these centres was such that patient recruitment 
never got off the ground. Moreover, the number of patients recruited by four other 
centres dropped off during the trial. In most cases this was due to reorganisation 
within the institution that led to changes in the personnel or management aims of 
departments. On the basis of this experience, we advise that trials should not last 
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Figure 1  Inclusion during the previous 12 months
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In the end we recruited 122 patients in 5 years and not the intended 155 pa-
tients in 3 years. Nevertheless, our study is one of the largest studies of psychotic de-
pression – only two other studies (Rothschild et al 2004), also with three treatment 
arms (including placebo), had slightly more patients (124 and 125, respectively). 
However, these two studies also had a very high dropout rate (73 of 124, 59.9%; and 
66 of 125, 52.8%, respectively). In our study, relatively few patients (n=22, 18.0%) 
dropped out: 6 patients because of serious adverse events, and 16 for other reasons. 
This low drop-out is probably because we included only hospitalised patients and 
because the logistics of the study were sound. Of course, it is also important that the 
trial investigators were motivated and agreed with the rationale of the study.
 Results
Our study was the first to show that the combination of an antidepressant plus 
an antipsychotic is more effective than an antidepressant alone. On the primary 
outcome (response)  the combination of venlafaxine plus quetiapine was more ef-
fective than venlafaxine alone, with a trend but no significant difference between 
venlafaxine plus quetiapine and imipramine, and no significant difference between 
imipramine and venlafaxine. Secondary outcomes followed the same pattern. The 
rate of remission was better with venlafaxine plus quetiapine than with imipramine 
with no significant difference compared with venlafaxine, and no significant dif-
ference between imipramine and venlafaxine. Our results provide support for the 
clinical view that psychotic depression should be treated with a combination of an 
antidepressant plus an antipsychotic (venlafaxine plus quetiapine) and not with an 
antidepressant (venlafaxine) alone. Whether this is also true for imipramine mo-
notherapy cannot be concluded from the present data (possibly because of lack of 
power due to small numbers) but is probably likely.
 Addition of the results of our study to those of our meta-analysis3 (Wijkstra 
et al 2005) makes the difference between monotherapy with an antidepressant and 
combination therapy with an antidepressant plus an antipsychotic statistically sig-
nificant.






















































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
































































   
   
  
   




   
   
   




   

















   















   
   
 
   




   
   
   




   


















   












   
   
   
   






































































































































































































































































































   
   
   
   
   
   
   
   
   
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   





















   
   
   
   
   
   
   
   
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   



























































   
   
  
   




   
   
   




   















   










   
   
 
   




   
   
   




   















   












   
  
   




   
   
   




   















   











   
   
 
   




   
   
   




   
















   











   
   
   
   





























































































































The availability of the data from our RCT means that we need to adapt one of 
the conclusions of our Cochrane review, namely, that there is no evidence that the 
combination of an antidepressant plus an antipsychotic is more effective than an 
antidepressant alone. There is now evidence that antidepressant plus antipsychotic 
combination therapy is more effective than antidepressant monotherapy. 
 Comments and limitations
It proved difficult to publish our RCT; it was rejected by three American journals 
(Archives of General Psychiatry, American Journal of Psychiatry, and Journal of 
Clinical Psychiatry). We consider it relevant and interesting to present en discuss 
here the various issues that were raised during the review process.
The first criticism raised in all reviews was that we did not include a 
placebo-treated group, so that we could not demonstrate the efficacy of the tested 
medication. This is true, but we considered it unethical to treat these severely ill 
patients with placebo while there is effective treatment available, since lack of such 
treatment could be harmful to the patients. Moreover, we considered a relevant 
placebo response extremely unlikely in patients with a severe depression such as 
psychotic depression. There appears to be an inverse relation between the severity 
of depression and the placebo response, with more severely depressed patients with 
high HAM-D scores having a low response to placebo.4 Neverthless, four previous 
studies had a placebo arm. Two of these studies  indeed reported placebo response 
rates of less than 10%,5,6 but two other, very recent studies reported placebo res-
ponse rates of 30–50%7,8 The difference in placebo response rates between these 
two latter studies and the previous studies may be due to differences in treatment 
setting (short duration of hospitalisation in the USA ), study populations (unknown, 
but possibly high proportion of patients without insurance in the USA), patient se-
lection (inclusion of less severely ill patients who did not need to be admitted and 
who could go without treatment for 2 weeks), and/or study design (patients able to 
be off medication for 2 weeks after diagnosis and inclusion, and hospital admission 
considered to be a confounder). We would like to argue that most likely patients 
who respond to placebo within 1 or 2 weeks do not have psychotic depression. We 
do not know whether our response to this criticism was convincing, but one of the 
journals (Archives of General Psychiatry) has recently accepted for publication a 
paper on a RCT with psychotically depressed patients comparing olanzapine with 
olanzapine plus sertraline without a placebo arm.9
 A second criticism raised in all reviews was that our study was underpo-
wered in that we failed to recruit the projected 155 patients, but only 122 patients. 
This is a valid point. However, given the trend in our results, we do not think that 
the inclusion of 155 patients would have resulted in a much more robust and sta-
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tistically significant difference between venlaflaxine plus quetiapine combination 
therapy and imipramine monotherapy. If the observed difference of 13.5% between 
the venlafaxine-quetiapine combination en imipramine should be the real diffe-
rence, we would have needed 210 patients in each arm to detect this difference sta-
tistically. Nevertheless, we found a significant difference of 32.5% in the response 
(the primary outcome) to venlafaxine plus quetiapine versus venlafaxine alone. Mo-
reover, our study still is the largest of its type (122 patients, 40 patients per study 
arm) to date. In retrospect, the design was ambitious and it would have been better 
to have had two rather than three treatment arms, comparing only the combina-
tion of an antidepressant plus an antipsychotic versus an antidepressant alone. The 
imipramine arm was not necessary to answer our main research question, namely, 
whether combination therapy with an antidepressant plus an antipsychotic is more 
effective than monotherapy with an antidepressant. Post-hoc, the 122 patients we 
recruited would have provided enough power for a two-armed study.
 A third criticism raised in all reviews was that treatment assignment was 
unblinded for each patient after he/she had completed the study. This contrave-
nes the convention for placebo-controlled studies that unblinding of medication 
assignment occurs only after the last patient has completed the study. In our study, 
unblinding occurred per patient after that patient had completed the study, but only 
after all the data for that patient had been checked and entered into the database. 
Thus unblinding usually occurred 1–3 weeks after patients completed the 7-week 
study. We considered this desirable so that patients could receive optimal treat-
ment as soon as possible after his completion of the acute trial. For patients whose 
response was still insufficient, further treatment often involved an antipsychotic 
(or another intervention), and for patients with an adequate response, the decision 
needed to be taken as to whether to continue with an antidepressant alone or with 
combination therapy. In addition, there were logistic and therapeutic arguments 
not to treat patients double-blind for maximally 3 years (and even 5 years): some 
patients were followed up in another institute, we did not have enough double-
blind medication, and, most importantly, we considered it not justified to continue 
the antipsychotic in the patients who had responded to the combination arm with 
antipsychotic for op to 3 (or 5) years. From a methodological point of view, we had 
anticipated this criticism and therefore checked whether blinding of the study was 
preserved by asking the treating physician of each patient to guess study medica-
tion prior to unblinding. By doing this we could prove that the quality of blinding 
was very high: the agreement between guessed and actual medication was very low 
(Kappa 0.14).
 Another issue raised in some of the reviews is whether the three arm study 
was the optimal design. An option would heave been to include a fourth arm: the 
combination of imipramine with quetiapine. For practical reasons we never con-
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sidered this seriously, as it would have increased the needed number of patients 
to 210 (i.e. by another 33%). However, in retrospect this would also have created 
another option: a combination of two RCTs simultaneously; a RCT comparing imi-
pramine and venlafaxine and a RCT comparing quetiapine and placebo. This would 
have allowed other comparisons as well: an antidepressant alone (placebo plus ei-
ther venlafaxine or imipramine) versus the combination of an antidepressant and 
an antipsychotic (quetiapine plus either venlafaxine or imipramine) as well as the 
comparison of venlafaxine (with either placebo or quetiapine) versus imipramine 
(also with either placebo or quetiapine). Theoretically, for such a design we would 
not have needed the full number of 210 patients.
 Our study is not the only study that was done in the recent years. Another 
recent large study9 focused on the comparison of an antipsychotic alone with the 
combination of an antipsychotic plus an antidepressant: olanzapine plus placebo 
versus olanzapine plus sertraline. This would appear to be an important question 
in the United States, where these studies originated, even though there was already 
evidence that antipsychotic monotherapy is less effective than combination therapy 
with an antipsychotic plus an antidepressant.3 A major limitation of this study was 
the high drop-out of 45%, which severely compromised the validity of this study. 
 Inclusion of the data of the study of Meyers et al9 in our Cochrane meta-
analysis further strengthened our conclusion, namely, that monotherapy with an 
antipsychotic is not a good treatment for patients with psychotic depression.   

















































































































   
   
   
   
   
   
   
   
   
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   






















   
   
   
   
   
   
   
   
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   







































































   
   
  
   




   
   
   




   































   
   




   
   
   




   
















   













   
   




   
   
   




   
















   









   
   
   
   


















































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   































































   
   
   
   




   
   
   




   




























   
   




   
   
   




   

















   










   
   




   
   
   




   
















   







   
   
   
   




   
   
   





   

















   










   
   
   
   

































































































































In conclusion, the study of Meyers et al9 confirms that antipsychotic 
monotherapy is not an appropriate treatment for patients with psychotic depression 
and our findings for the first time showed that antidepressant monotherapy is less 
effective than combination therapy with an antidepressant plus an antipsychotic in 
these patients. 
 Long-term response to successful pharmacological treatment 
 of psychotic depression
The results of the first 4 months of continuation treatment of the patients who 
responded to treatment in the 7-week double-blind acute study were described in 
chapter 6. As mentioned above, for therapeutic reasons it was undesirable and 
for logistic reasons it was impractical to continue treatment double-blind during 
this period. Moreover, there were too few patients in each treatment arm for 
statistical analysis. For these reasons, we chose to perform the analysis as if it was a 
naturalistic, open-label, study. The same medication that was effective in the acute 
treatment trial proved to remain effective during the follow-up study and was well 
tolerated. Thirty-five patients (59.3%) who were responders in the acute treatment 
trial achieved remission during the follow-up study. Moreover, the remission rate 
increased among those who completed the follow-up study (86.8%, 46 of 53), 
suggesting that further improvement on the same medication is possible after 7 
weeks of treatment with or without an antipsychotic.
 In the literature, authors are increasingly favouring remission status (Ha-
milton Depression Rating Scale, HAM-D, <7) as outcome variable instead of res-
ponse status (HAM-D <14), because the chance of recurrence is lower in patients 
in remission.10,11,12 We found that nearly all responders became remitters after 4 
months. This suggests that response still can be used as a major outcome variable 
because with continued treatment, responders have a real chance of becoming re-
mitters.
 Lithium addition
The aim of the study described in chapter 7 was to compare imipramine, venlafaxi-
ne, and venlafaxine plus quetiapine (phase I), followed by lithium addition (phase 
II) in patients who failed to respond to treatment in phase I. Since only 15 patients 
were included in phase II, evaluation of the two-phase treatment strategies was 
impossible. Therefore, also lithium addition was evaluated as if it was an open-label 
study. Nine of 15 patients (60%) attained remission, defined as a final HAM-D 
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score ≤ 7. The same number of patients achieved a response (HAM-D reduction 
≥ 50%). All 9 remitters had a sustained remission during the 4-month follow-up 
period. Lithium addition appears to be effective in psychotic depression, but these 
data from an open-label study are insufficient grounds for this treatment to be con-
sidered evidence based. 
 Conclusions
A number of conclusions can be drawn from the results of the various studies des-
cribed in this thesis.
Although there are now more studies, the pharmacological treatment of 1. 
psychotic depression remains understudied.
Guideline recommendations for the pharmacological treatment of psychotic 2. 
depression are not always evidence based.
It was difficult to perform a RCT involving patients with psychotic depression, 3. 
which in part explains why so little is known about the treatment of this disorder. 
Another important reason is that the pharmaceutical industry does not consider 
psychotic depression to be a relevant indication for a new antidepressant or 
drug and until recently had not expressed interest in developing agents for this 
indication.
Until this study, there was insufficient evidence to support the view that psychotic 4. 
depression can best be treated with a combination of an antidepressant plus an 
antipsychotic instead of an antidepressant alone. With our study, there is now 
evidence that monotherapy with an antidepressant (venlafaxine) is less effective 
than combination therapy with an antidepressant plus an antidepressant 
(venlafaxine plus quetiapine). Whether this conclusion can be extrapolated to 
other antidepressants and antipsychotics, remains unclear.
If a response is achieved after treatment with either a combination of an 5. 
antidepressant plus an antipsychotic or with an antidepressant alone, then it is 
worthwhile continuing the same medication for at least 4 months.
Treatment with the combination of an antidepressant plus an antipsychotic 6. 
is also more effective than an antipsychotic alone. This has now been shown 
for the classical antipsychotic perphenazine and for the atypical antipsychotic 
olanzapine. 
If patients do not respond to treatment with either a combination of an 7. 




Important clinical questions that have yet to be answered include:
Is treatment with the combination of an antidepressant plus an antipsychotic 1. 
indeed more effective than treatment with an antidepressant alone? This needs 
to be verified in more studies with different antidepressants and different 
antipychotics.
Is the combination imipramine plus quetiapine more effective than the 2. 
combination venlaflaxine plus quetiapine?
Is quetiapine monotherapy a therapeutic option? It may be possible that 3. 
quetiapine is an exception with regard to its antidepressant activity in 
comparison to other atypical antipsychotics.13,14,15
How long should patients remain on treatment once response (and remission) 4. 
to the combination of an antidepressant and an antipsychotic has been achieved? 
Should the combination of an antidepressant plus an antipsychotic be used as 
follow-up treatment or would it be possible to taper the antidepressant or the 
antipsychotic and to continue one of the treatments as monotherapy?
What is the short-term and long-term efficacy of ECT in comparison with 5. 
combination therapy with an antidepressant plus an antipsychotic?
Is the addition of lithium effective in non-responders? And what is the effect of 6. 
other add-on agents such as mifepristone?8
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 Clinical implications
The results of the studies described in this thesis provide more evidence that psy-
chotic depression can best be treated pharmacologically with a combination of an 
antidepressant plus an antipsychotic. The combination investigated, venlaflaxine 
and quetiapine, is well tolerated. 
 Patients with psychotic depression should be treated for longer than 4 
weeks before deciding whether treatment is effective or not. Longer treatment pro-
bably is useful because patients continued to show improvement after 7 weeks of 
treatment. Moreover, patients who respond to treatment (HAM-D <14) may go into 
remission (HAM-D <7) if the treatment to which they responded, is continued. This 
was a post-hoc finding in our study when treatment was continued on a naturalistic 
basis (patients were not re-randomized after completion of the 7-week study) and 
should be confirmed in other studies. Lithium would appear to be a treatment op-
tion in non-responders.
 Continued treatment for at least 4 months with the same medication to 
which the patient responded is probably effective. However, it is not known for how 
long thereafter patients should be treated. Data from studies among patients with 
depression without psychotic features indicate that continued treatment for up to 
years may be desirable.16 Moreover, if combination therapy with an antidepressant 
plus an antipsychotic has proven to be effective, it is not clear whether it is possible 
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